Novo Nordisk A/S (NYSE:NVO) Trading 1.1% Higher

Novo Nordisk A/S (NYSE:NVO - Get Free Report) traded up 1.1% on Friday . The stock traded as high as $127.30 and last traded at $127.15. 1,255,884 shares traded hands during trading, a decline of 74% from the average session volume of 4,768,842 shares. The stock had previously closed at $125.79.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Cantor Fitzgerald reissued an "overweight" rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. UBS Group assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a "neutral" rating for the company. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an "outperform" rating and a $163.00 price objective for the company. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 price objective for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $133.60.

Novo Nordisk A/S Stock Performance

The stock has a market capitalization of $569.29 billion, a P/E ratio of 47.05, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. The company has a 50-day moving average price of $126.80 and a two-hundred day moving average price of $111.74. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts' consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The business had revenue of $9.51 billion for the quarter, compared to the consensus estimate of $9.14 billion. On average, equities analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were paid a dividend of $0.664 per share. This is an increase from Novo Nordisk A/S's previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S's dividend payout ratio is 49.17%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Pacific Center for Financial Services increased its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock worth $25,000 after purchasing an additional 135 shares in the last quarter. First PREMIER Bank bought a new stake in Novo Nordisk A/S during the 1st quarter worth approximately $25,000. Copeland Capital Management LLC increased its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company's stock worth $26,000 after purchasing an additional 141 shares in the last quarter. Bell Investment Advisors Inc increased its holdings in Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company's stock worth $26,000 after purchasing an additional 127 shares in the last quarter. Finally, CNB Bank bought a new stake in Novo Nordisk A/S during the 4th quarter worth approximately $26,000. 11.54% of the stock is owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.